We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Electronic Device May Help Diagnose Early Bladder Cancer

By LabMedica International staff writers
Posted on 09 Aug 2019
Print article
Image: A new study suggests that cutting-edge electronic devices can help doctors diagnose early stage bladder cancer (Photo courtesy of Ana Sandoiu).
Image: A new study suggests that cutting-edge electronic devices can help doctors diagnose early stage bladder cancer (Photo courtesy of Ana Sandoiu).
It is estimated that bladder cancer will affect 80,470 people in the USA this year, and about 17,670 deaths are likely to result from these cases. Doctors diagnose approximately half of all bladder cancers while the cancer is still in situ, while in about one-third the disease has already spread to other parts of the bladder.

Currently, the most common ways of detecting bladder cancer are cystoscopies and urine cytology tests. The former are costly, invasive, and heavily reliant on how the operator performs them, while the latter are not very effective at detecting cancer in its early stages. Additionally, cytology tests are prone to error, as they are not the best tool for telling the difference between inflammation and malignancy.

Bioengineers at the Polytechnic University of València (València, Spain) and their colleagues have developed a complex electronic device as a possible new, efficient, simple, and cost-effective way of detecting bladder cancer in its early stages and monitoring people living with bladder cancer. The devices are called electronic tongues, which are a voltammetric device that can "mimic" the mechanism of human taste by using pattern-information software and sensors that can detect soluble compounds.

The scientists built on previous studies that revealed metabolic differences in the urine of people who had bladder cancer. These previous studies used established metabolomic techniques, such as liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy, to look at the metabolic profiles both before and after surgery. Bladder cancer has a high relapse rate, which is why monitoring patients is particularly important. In 2012, bladder cancer "was the ninth most common malignancy worldwide, with 430,000 newly diagnosed cases.

M. Carmen Martínez Bisbal, PhD, a biochemist and co-author of the study, said, “The preliminary results of this study, with a 75% accuracy rate, indicate that the shapes of current waveforms induced in urine through pulse voltammetry could allow, with an appropriate processing of the data, for a noninvasive diagnosis in the monitoring of patients with bladder cancer.” The study was presented at the XIII International Workshop on Sensors and Molecular Recognition held July 4-5, 2019, in Valencia, Spain.

Related Links:
Polytechnic University of València

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.